Related references
Note: Only part of the references are listed.2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
Jean-Philippe Collet et al.
EUROPEAN HEART JOURNAL (2021)
A systematic review and meta-analysis on the effectiveness of an invasive strategy compared to a conservative approach in patients > 65 years old with non-ST elevation acute coronary syndrome
Joan Dymphna P. Reano et al.
PLOS ONE (2020)
Ticagrelor or Clopidogrel in Elderly Patients With Myocardial Infarction When the Choice Makes the Difference
Piera Capranzano et al.
CIRCULATION (2020)
Comparison Between Ticagrelor and Clopidogrel in Elderly Patients With an Acute Coronary Syndrome Insights From the SWEDEHEART Registry
Karolina Szummer et al.
CIRCULATION (2020)
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial
Johanne Silvain et al.
LANCET (2020)
Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management A Randomized Clinical Trial
Duk-Woo Park et al.
CIRCULATION (2019)
Ticagrelor with or without Aspirin in High-Risk Patients after PCI
R. Mehran et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)
Borja Ibanez et al.
EUROPEAN HEART JOURNAL (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
Marco Valgimigli et al.
EUROPEAN HEART JOURNAL (2018)
Fatal or Irreversible Bleeding and Ischemic Events With Rivaroxaban in Acute Coronary Syndrome
C. Michael Gibson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention A systematic review and Meta-Analysis (2007-2017)
Wenjun Guan et al.
MEDICINE (2018)
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients
Tullio Palmerini et al.
EUROPEAN HEART JOURNAL (2017)
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)
Marco Roffi et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy and safety outcomes of ticagrelor compared with clopidogrel in elderly Chinese patients with acute coronary syndrome
Huidong Wang et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial
Steen Husted et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2012)
Antithrombotic Therapy in the Elderly
Davide Capodanno et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Antiplatelet Therapy in Older Adults with Non-ST-Segment Elevation Acute Coronary Syndrome: Considering Risks and Benefits
Renato D. Lopes et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A validated prediction model for all forms of acute coronary syndrome - Estimating the risk of 6-month postdischarge death in an international registry
KA Eagle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Share Paper
